138 related articles for article (PubMed ID: 27447478)
1. Free/Total Serum Prostate-Specific Antigen Ratio in Women with Colorectal Cancer Has Prognostic Significance.
Duraker N; Çaynak ZC; Trabulus DC
J Gastrointest Cancer; 2017 Mar; 48(1):8-12. PubMed ID: 27447478
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
Björk T; Lilja H; Christensson A
BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
[TBL] [Abstract][Full Text] [Related]
3. Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
Jeong JU; Nam TK; Song JY; Yoon MS; Ahn SJ; Chung WK; Cho IJ; Kim YH; Cho SH; Jung SI; Kang TW; Kwon DD
PLoS One; 2021; 16(3):e0248461. PubMed ID: 33711055
[TBL] [Abstract][Full Text] [Related]
4. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
5. Association between percent-free prostate-specific antigen and glomerular filtration rate in transrectal ultrasound-guided biopsy-proven patients with prostate-specific antigen levels ranging from 4 to 10 ng/ml.
Kim JH; Shim JS; Bae JH; Park HS; Moon du G; Kwon SS; Park JY
World J Urol; 2013 Apr; 31(2):313-8. PubMed ID: 23283411
[TBL] [Abstract][Full Text] [Related]
6. Identification of Most Aggressive Carcinoma Among Patients Diagnosed With Prostate Cancer Using Mathematical Modeling of Prostate-Specific Antigen Increases.
de Charry F; Colomban O; You B; Ruffion A; Paparel P; Wilbaux M; Tod M; Freyer G; Perrin P
Clin Genitourin Cancer; 2016 Jun; 14(3):210-217.e1. PubMed ID: 26804605
[TBL] [Abstract][Full Text] [Related]
7. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract][Full Text] [Related]
8. [The percentage of free prostate specific antigen used in detecting prostate cancer].
Yang L; Fang Z; Song J; Deng S
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
Hong SK; Park HZ; Lee WK; Kim DS; Lee JS; Doo SH; Jeong SJ; Yoon CY; Byun SS; Lee SE
Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
[TBL] [Abstract][Full Text] [Related]
10. Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue volume in patients undergoing radical prostatectomy: a new predictor of biochemical recurrence in localized or locally advanced prostate cancer.
Ku JH; Moon KC; Cho SY; Kwak C; Kim HH
Asian J Androl; 2011 Mar; 13(2):248-53. PubMed ID: 21102474
[TBL] [Abstract][Full Text] [Related]
11. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
12. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
[TBL] [Abstract][Full Text] [Related]
13. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
15. Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen.
Lechevallier E; Eghazarian C; Ortega JC; Roux F; Coulange C
Urology; 1999 Nov; 54(5):857-61. PubMed ID: 10565747
[TBL] [Abstract][Full Text] [Related]
16. The 1989 patterns of care study for prostate cancer: five-year outcomes.
Chuba PJ; Moughan J; Forman JD; Owen J; Hanks G
Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):325-34. PubMed ID: 11380218
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
19. Measurement of serum total and free prostate-specific antigen in women with colorectal carcinoma.
Duraker N; Can D; Parilti M
Br J Cancer; 2002 Jan; 86(2):203-6. PubMed ID: 11870506
[TBL] [Abstract][Full Text] [Related]
20. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]